Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447194 | 0.84 | THRB (0.41) | COMTMAPTPOLBTP53NPC1 | |
| SCHEMBL1447346 | 0.83 | COMT (0.59) | COMTMAPTPOLBNPC1RAB9A | |
| SCHEMBL1447426 | 0.83 | COMT (0.41) | COMTMAPTPOLBTP53RAB9A | |
| SCHEMBL1447072 | 0.83 | COMT (0.59) | COMTMAPTPOLBNPC1RAB9A | |
| SCHEMBL1447566 | 0.82 | COMT (0.52) | COMTMAPTPOLBTP53NPC1 | |
| SCHEMBL1447252 | 0.82 | COMT (0.38) | COMTMAPTPOLBTP53RAB9A | |
| SCHEMBL1447262 | 0.81 | COMT (0.48) | COMTMAPTTP53NPC1RAB9A | |
| SCHEMBL1447180 | 0.81 | COMT (0.52) | COMTMAPTTP53NPC1RAB9A | |
| SCHEMBL3584646 | 0.81 | MAPT (0.50) | COMTMAPTPOLBTP53NPC1 | |
| SCHEMBL1448324 | 0.81 | COMT (0.54) | COMTMAPTPOLBTP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388999-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL PORTELA & CA SA (PT) | 2022-12-08 | — | — | US | disclosed |
| US-20200102295-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2020-04-02 | — | — | US | disclosed |
| US-10336740-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2019-07-02 | — | — | US | disclosed |
| US-20190144436-A1 | ADMINISTRATION REGIME FOR NITROCATECHOLS | BIAL - PORTELA & CA, S.A. (PT) | 2019-05-16 | — | — | US | disclosed |
| US-20170362213-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & COMPANHIA, S.A. (PT) | 2017-12-21 | — | — | US | disclosed |
| US-9550759-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2017-01-24 | — | — | US | disclosed |
| EP-1907382-B1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL PORTELA & CA SA (PT) | 2015-05-27 | — | — | EP | disclosed |
| US-20150072977-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2015-03-12 | — | — | US | disclosed |
| US-8907099-B2 | Nitrocatechol derivatives as COMT inhibitors | BIAL-PORTELA & CA, S.A. (PT) | 2014-12-09 | — | — | US | disclosed |
| US-20120196904-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & CA., S.A. (PT) | 2012-08-02 | — | — | US | disclosed |
| US-8168793-B2 | Nitrocatechol derivatives as COMT inhibitors | PORTELA & CA., S.A. (PT) | 2012-05-01 | — | — | US | disclosed |
| EP-2307020-A1 | ADMINISTRATION REGIME FOR NITROCATECHOLS | Bial-Portela & CA, S.A. (PT) | 2011-04-13 | — | — | EP | disclosed |
| EP-2301934-A1 | Nitrocatechol derivatives as COMT inhibitors | BIAL - Portela & Ca., S.A. (PT) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010014025-A1 | ADMINISTRATION REGIME FOR NITROCATECHOLS | BIAL - PORTELA & CA., S.A. (PT) | 2010-02-04 | — | — | WO | disclosed |
| US-20090054437-A1 | Nitrocatechol Derivatives as Comt Inhibitors | PORTELA & CA., S.A. (PT) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362213-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885MAPT 694/4885POLB 785/4885 |
| US-20150072977-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885MAPT 694/4885POLB 785/4885 |
| US-20220388999-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885MAPT 664/4885POLB 820/4885 |
| US-20090054437-A1 | Nitrocatechol Derivatives as Comt Inhibitors | COMT, PNMT, OPRK1 | COMT 1/4885MAPT 694/4885POLB 785/4885 |
| US-20190144436-A1 | ADMINISTRATION REGIME FOR NITROCATECHOLS | HCRTR1, MTNR1A, CHRM1 | COMT 19/4885MAPT 1438/4885POLB 3039/4885 |
| US-10336740-B2 | Nitrocatechol derivatives as COMT inhibitors | COMT, PNMT, OPRK1 | COMT 1/4885MAPT 694/4885POLB 785/4885 |
| US-20200102295-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885MAPT 664/4885POLB 820/4885 |
| US-20120196904-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | COMT, PNMT, OPRK1 | COMT 1/4885MAPT 694/4885POLB 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.